Inovio Pharmaceuticals shares were down 20% to $2.99 after hours as the company said it plans to sell stock and accompanying warrants.

(Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals Inc. closed $10.99 below its 52-week high ($14.75), which the company reached on April 1st.

Analyst Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non ...

Inovio (INO) announced data from a retrospective trial showing that the number of Recurrent Respiratory Papillomatosis , or RRP, patients ...

INOVIO (NASDAQ: INO) has announced a stock option grant to a newly hired employee under its 2022 Inducement Plan. The award ...

TORONTO, November 29, 2024--Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) today announced the signing of an exchange contract for the sale of the Sablière property to a third ...

Shares of Inovio Pharmaceuticals ($INO) slipped nearly 2% on Thursday afternoon ahead of the company’s third-quarter results, with retail sentiment staying bullish ...

Short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) increased during the last reporting ... on the decline of Inovio Pharmaceuticals's stock. Short interest data is updated every two weeks.

INOVIO (INO) reported data from a retrospective trial showing that the number of Recurrent Respiratory Papillomatosis patients ...

In other recent news, Inovio Pharmaceuticals (NASDAQ:INO) has entered into a sales agreement with Oppenheimer & Co. Inc. The agreement, which allows for the potential sale of common stock at the ...